During the past decade, Regionshospitalet Viborg conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 11 clinical trials were completed, i.e. on average, 25.6% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 8 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regionshospitalet Viborg" #1 sponsor was "University of Aarhus" with 13 trials, followed by "Amgen" with 4 trials sponsored, "Copenhagen University Hospital at Herlev" with 3 trials sponsored, "Rigshospitalet, Denmark" with 3 trials sponsored and "Aalborg University" with 3 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regionshospitalet Viborg" #1 collaborator was "Aarhus University Hospital" with 9 trials as a collaborator, "Regionshospitalet Viborg, Skive" with 7 trials as a collaborator, "Randers Regional Hospital" with 5 trials as a collaborator, "Aalborg University Hospital" with 4 trials as a collaborator and "Oslo University Hospital" with 4 trials as a collaborator. Other collaborators include 102 different institutions and companies that were collaborators in the rest 82 trials.

According to Clinical.Site data, the most researched conditions in "Regionshospitalet Viborg" are "Atrial Fibrillation" (4 trials), "Atherosclerotic Cardiovascular Disease" (2 trials), "Breast Cancer" (2 trials), "Chronic Kidney Disease" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "Regionshospitalet Viborg" in a lesser frequency.

Most popular intervention types in "Regionshospitalet Viborg" are "Drug" (27 trials), "Procedure" (16 trials), "Device" (8 trials), "Other" (7 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Dexrazoxane" (2 trials), "Evolocumab" (2 trials), "Exercise-group" (2 trials) and "Prednisolone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Regionshospitalet Viborg" are 57 trials for "All" genders, 8 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Regionshospitalet Viborg". undefined are not yet recruiting, 18 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 38 completed trials in Regionshospitalet Viborg, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Regionshospitalet Viborg, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 30 trials that are defined as “Not Applicable".